Rosetta Genomics Completes $4.5M Financing | GenomeWeb

NEW YORK (GenomeWeb News) – Rosetta Genomics said yesterday that it has completed its previously announced direct offering of approximately $5.1 million in securities.

Rosetta has received net proceeds of approximately $4.5 million after deducting placement agent fees and other offering expenses.

The molecular diagnostics developer said that it plans to use the $4.5 million in proceeds from the offering for general corporate purposes and to support the development of its microRNA-based diagnostic pipeline.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.